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ABSTRACT
Objective: This study aimed to develop and validate a short,
simple, patient-completed instrument for identifying patients
with congestion in a 15-day study. Allergic rhinitis (AR) is the
most common allergic condition worldwide, with congestion
as one of the most salient symptoms. Nevertheless, there is no
short screening tool designed speciﬁcally to identify conges-
tion that can help patients make decisions about seeking
treatment.
Methods: Patients (N = 354) received a clinical exam to
conﬁrm congestion and assess its possible causes including
conﬁrmation of AR. They completed the 13-item draft of the
Congestion Quantiﬁer (CQ) and ﬁve additional patient-
reported outcome instruments.
Results: The 13-item draft CQ was reduced to a seven-
item version, the CQ7. Internal consistency reliability was
0.93; test–retest reliability = 0.85. Construct validity was
demonstrated by signiﬁcant correlations with the Medical
Outcomes Study Sleep Scale, the Work Productivity and
Activity Impairment Questionnaire—Allergy Speciﬁc, and
the Positive Affect and Negative Affect Scale Fatigue subscale
(r = 0.23–0.67). The CQ7 can discriminate between controls
and patients (AUC > 0.9). Moreover, it can discriminate
between different levels of severity of symptoms of AR. A
score of 7 provided optimum balance of sensitivity (91%),
speciﬁcity (86%), and correct classiﬁcation (90%) for
detecting congestion.
Conclusion: The CQ7 is reliable, valid, and responsive to
differences in severity of nasal congestion. The CQ7 can
identify patients with congestion that may need to be evalu-
ated by a clinician.
Keywords: allergic rhinitis, congestion, self-administered
screener.
Introduction
Allergic rhinitis (AR) is the most common allergic con-
dition worldwide, affecting more than 150 million
people in North America, Europe, and Japan alone
and its prevalence has increased in the past 15 years
[1]. More than 40 million Americans (around 13%)
and almost one-fourth of the population in Europe are
affected by AR [2–4]. In 2002, almost 2% of the nearly
890 million ofﬁce visits (or about 14 million) in the
United States were for the primary complaint of AR,
with most (63%) of these seen by primary care
physicians [5].
Symptoms associated with AR—rhinorrhea, sneez-
ing, itching or watery eyes, and nasal con-
gestion—result in increased health-care costs [6–10],
reduced productivity at work or school [6,7,9,10],
reduced quality of life [9,11,12], and impaired sleep
resulting in daytime somnolence [10,12,13]. Allergies
are the sixth leading cause of chronic disease in the
United States, costing the health-care system an esti-
mated $1.16 billion to $4.5 billion [14]. These costs
increase to more than $8 billion when indirect costs
(e.g., lost productivity in the work place or employee
absenteeism) are included [15]. Estimated costs for
Europe are also high, with costs of AR directly attrib-
utable to health care or indirectly resulting from
worker absenteeism estimated in the billions of Euros
[6].
In spite of the high prevalence and costly impact of
this condition, it is estimated that only about 12% (4.8
million persons) of those with AR in the United States
take prescription drugs for this condition; most go
without treatment or self-treat with over-the-counter
medications [16]. Moreover, there is evidence that
almost half (45%) of cases of AR may go undiagnosed
[17].
Clearly, AR may be underdiagnosed and the symp-
toms associated with AR represent a signiﬁcant burden
to patients, the workplace, and the health-care system.
Some symptoms of AR appear to be more problematic
than others. Patients with AR report that nasal
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congestion is one of several, if not the most, bother-
some symptoms [2]. Further, evidence suggests that
there is persistent mucosal inﬂammation and conges-
tion even during asymptomatic periods [18]. Conse-
quently, patients may experience a low level of
congestion that impedes breathing and daily function
but not address it given the relative reduction in con-
gestion and other symptoms. It would therefore be
beneﬁcial to have methods that can help patients self-
identify the severity of their congestion symptoms,
determine whether they should seek medical care, and
encourage patient–clinician communication to explore
possible treatment for congestion.
Numerous validated, disease-speciﬁc patient-
reported outcome (PRO) instruments have been devel-
oped to assess symptom severity in AR [19] and its
impact [20–22]. Nevertheless, there is no short, easy-
to-administer screening tool designed speciﬁcally to
identify nasal congestion and that can help patients
make decisions about seeking treatment. The current
study was designed to create and validate a congestion
screening tool that is derived from patients and clinical
expert input.
Methods
Item Generation
Development of the Congestion Quantiﬁer (CQ) Test
began with a literature search and examination of key
indices of symptoms associated with AR. Items were
generated in conjunction with two clinical experts who
noted complaints most commonly reported by their
patients; an initial set of eight items was then reviewed
for face validity by ﬁve clinical experts (three otolaryn-
gologists and two allergists). An additional four items
were added and the response scale was established. A
ﬁnal item regarding symptom duration of greater than
2 weeks was included based on clinician recommenda-
tion to differentiate chronic AR from acute viral or
bacterial infections and as a way of differentiating
severity from duration. The ﬁnal draft version con-
sisted of 13 items, 12 scored on a 5-point scale from
“none of the time” to “all of the time” and one item on
symptom duration. Patient input was obtained
through open-ended questions asking about the impact
of morning allergy symptoms and nasal stufﬁness/
congestion on their lives.
Study Design
The screener was included in a protocol for a 15-day
naturalistic observational study examining the rela-
tionship between seasonal and perennial AR and PROs
of sleep, work productivity, and functional impair-
ment. After approval was obtained from a central
institutional review board and informed consent was
provided by each participant, data were collected from
patients during outpatient primary care or specialist
(allergist or otolaryngologist) ofﬁce visits in the United
States between September and November 2005. All
patients were required to be 18 years of age or older,
able to read, write, and speak English. Three diagnos-
tic groups were recruited for the study: those with AR
conﬁrmed via positive skin test in prior 12 months and
nasal rhinorrhea (discharge) score of moderate or
severe (score of at least 2 on scale of 0–3 to allow
selection of patients comparable to those in previous
clinical trials studying AR); those who self-identiﬁed
with congestion (hereafter Congestion) with signs and
symptoms of congestion; and normal controls.
The Congestion patients were not required to
present with a speciﬁc level of nasal congestion sever-
ity. This allowed for variability in congestion among
these patients. Eligibility for the congestion arm
required positive clinical exam for congestion due to
AR, nasal structural abnormalities including nasal
polyps, or alternative rhinopathies (including non-AR)
for at least 7 days before enrollment. This group
afforded us the opportunity to see if the CQ had equal
applicability to patients who had not been clinically
conﬁrmed with AR. These two patient groups com-
pleted a clinical exam to rule out alternative or comor-
bid conditions (i.e., viral respiratory and bacterial
infections or chronic asthma). Control patients were
seen for a noncongestion-related complaint (e.g., mus-
culoskeletal, cardiovascular, or gastrointestinal condi-
tions). These patients were included to insure a full
range of CQ scores for sensitivity tests. All patients
underwent a clinical nasal exam.
Instruments
The CQ Test was administered to patients during the
study period, with ﬁve additional PRO instruments
measuring various aspects of nasal symptoms, sleep,
fatigue, and work and school productivity. These
PROs were used to assess the construct validity of the
screener. All instruments are brieﬂy described below.
Congestion Quantiﬁer Test. The initial draft of the
CQ was a self-administered 13-item questionnaire that
assessed symptoms and impact of congestion (Table 1).
Patients were asked about the frequency of nasal stufﬁ-
ness (during the day, at night, and upon waking
up), dry mouth/thirst, sinus pressure/facial pain, ear
popping/clogged ears, runny nose, breathing through
mouth, impact on sleep/work, ability to smell, snoring,
and duration of symptoms. The response scale ranged
from 0 = none of the time to 4 = all of the time. The
recall period was over the past week. Higher scores
indicated greater problems associated with congestion.
Allergic Rhinitis Impact Questions (ARIQ). The
ARIQ is composed of two open-ended questions that
were developed for this study. Their purpose is to elicit
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responses in the patients’ own words about the great-
est impact of morning allergy symptoms and nasal
stufﬁness/congestion on their lives.
Symptom Scale (AM and previous 12 hours). The
Symptom Scale is a PRO measure that assesses
common nasal symptoms (nasal drainage, nasal
congestion/stufﬁness, nasal itching, and sneezing) and
non-nasal symptoms (itching/burning eyes, tearing/
watering eyes, redness of eyes, itching of ears or palate,
and cough) associated with allergies on a 4-point scale
(0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe).
Participants were asked to indicate the severity of each
symptom over the previous 30 minutes and over the
previous 12 hours. Total Symptom Scale (TSS) scores
are obtained separately for each recall period version
(30 minutes, previous 12 hours) by summing the nine-
item scores, resulting in a range of overall severity
from 0 to 27 for AM 30 minutes and prior 12 hours.
Work Productivity and Activity Impairment
Questionnaire—Allergy Speciﬁc (WPAI-AS). The
WPAI-AS consists of nine items that measure work-
and activity-related impairment during the previous
week [22]. Domains covered include work productiv-
ity, school productivity, and ability to perform regular
daily activities. Response options include visual analog
scales and write-in items (e.g., hours missed in the past
week because of allergy symptoms). The following
subscales are generated: work impairment, impairment
in class, activity impairment, work time missed, overall
work impairment, class time missed, and overall class
impairment. A higher score indicates greater impair-
ment of work and school productivity and daily activi-
ties. Psychometric work by the developers provides
evidence of construct and discriminant validity as well
as responsiveness [22,23].
Positive Affect and Negative Affect Scale––Expanded
Form (PANAS-X). Three subscales from the
PANAS-X [24,25] were used to measure patient well-
being. The domains include sadness (5 items), joviality
(8 items), and fatigue (4 items). Patients were asked to
mark the extent to which they feel the way described
Table 1 Item content: draft screener for Congestion symptoms
During the past week . . .
None of
the time
A little of
the time
Some of
the time
Most of
the time
All of
the time
1. How often did you have nasal stufﬁness,
blockage, or congestion?

0

1

2

3

4
2. How often did you have sinus pressure
or pain in your face?

0

1

2

3

4
3. How often did you experience ear
popping or clogged or plugged ears?

0

1

2

3

4
4. How often did you have to breathe
through your mouth because you couldn’t
breathe through your nose?

0

1

2

3

4
5. How often did you have trouble smelling
things?

0

1

2

3

4
6. How often did you have difﬁculty
completely clearing your nose even after
repeated blowing?

0

1

2

3

4
7. How often did you have a runny nose? 
0

1

2

3

4
8. How often did any of these symptoms
affect your ability to work, learn in school,
or do the things you need to do?

0

1

2

3

4
During the past week . . .
None of
the time
(0 time/
week)
A little of
the time
(1–2
times/
week)
Some of
the time
(3–4
times/
week)
Most of
the time
(5–6
times/
week)
All of
the time
(more than
6 times/
week)
9. How often did you awaken in the
morning with nasal stufﬁness, blockage, or
congestion?

0

1

2

3

4
10. How often did you awaken in the
morning with a dry mouth or thirsty?

0

1

2

3

4
11. How often was your sleep affected by
your nasal stufﬁness, blockage, or
congestion?

0

1

2

3

4
12. Based on what others have told you, how
often did you snore during your sleep?

0

1

2

3

4
13. Have you had these symptoms for longer than the past 2 weeks?
0 No
1 Yes
Items 1, 2, 4, 6, 8, 9, and 11 were selected for the CQ7.
Range of CQ7: 0–28; a summed score of 7 or greater on the CQ7 items indicates that treatment should be explored.
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using a 5-point Likert scale ranging from very slightly/
not at all (1) to extremely (5).
Medical Outcomes Study 12-Item Sleep Scale
(MOS-12 Sleep Scale). The MOS-12 Sleep Scale is a
self-administered 12-item questionnaire that assesses
characteristics of sleep [26]. For this study the recall
period was the past week. The instrument consists of
seven sleep scales: sleep disturbance (initiation and
maintenance), snoring, shortness of breath or head-
ache, adequacy, somnolence, quantity, and optimal
sleep. Summary measures of different types of sleep
problems are captured in Sleep Index I and II. Items
were transformed to range from 0 to 100 and scales
are scored so that a higher score reﬂects a greater
amount of the quality implied by the subscale name
(e.g., a higher score on “sleep disturbance” means
greater sleep disturbance [27]). The MOS Sleep Scale
has evidence supporting internal consistency reliability
and construct validity [26,28].
Clinical and demographic information. At the time of
study enrollment, clinical information was collected
from a physical exam at the time of study enrollment
of the subject’s upper and lower respiratory tract
including eyes, ears, nasal cavities, turbinates, nasal
secretions, and vital signs such as temperature, blood
pressure, pulse, and respiration rate. Patients provided
demographic information on date of birth, sex, ethnic-
ity, marital status, employment, and education.
Assessment schedule. The clinical information was
completed at baseline only. The Symptom Scale (AM
within the past 30 minutes and for the prior 12 hours)
was completed as a daily diary in the morning upon
waking for the entire study. Only the baseline scores
for the TSS were used for validation analyses. The
congestion screener items were completed at baseline
and Day 15 for the conﬁrmed AR and Congestion
patients. All other measures were completed at base-
line and Days 7 and 15. Control subjects completed
the screener items only at baseline.
Analyses
Thematic analysis of ARIQ responses. The two open-
ended questions asking respondents about the impact
of congestion and morning allergy symptoms were
qualitatively analyzed for themes. The approach used
in grounded theory methodology for conducting a the-
matic analysis was employed [29]. In the ﬁrst phase,
open coding, responses are broken into smaller, key
components and given labels or a discrete meaning.
This was relatively straightforward given that patient
responses were generally very direct and speciﬁc. The
second phase, axial coding, involves organizing each of
the ﬁner categories or codes from the open-coding
phase into more general conceptual categories or
themes. The total number of category or thematic
mentions was summed across all patients.
Factor analyses. An exploratory factor analysis was
conducted using principal components factor analysis
(principal axis factoring) to evaluate the multidimen-
sionality of the set of screening items. The minimum
eigenvalue for factor retention was 1.0, although
values down to 0.7 were reviewed for possible factor
inclusion. Both orthogonal and oblique rotations were
permitted, based on expected correlation between
factors. In addition, squared multiple correlations
(also known as communalities) were evaluated for
each item. That is, each item was regressed on the
remaining items. These statistics indicate items that
have a lower relationship with the remaining items.
This yields additional information about items that
can be dropped because they do not measure common
content as strongly.
Internal consistency and test–retest reliability. Inter-
nal consistency (assessing an adjusted average inter-
item correlation for a set of items) was evaluated using
coefﬁcient alpha. Test–retest reliability for the screener
was assessed by computing intraclass correlation coef-
ﬁcient (ICC) comparing data from the baseline and
Day 15 visits in stable subjects.
Construct validation. To assess construct validity, ﬁnal
CQ scores obtained through the prior steps were
evaluated for correlation with the WPAI-AS, the MOS
Sleep Scale, and the PANAS-Fatigue. Prior research
has shown that AR has a signiﬁcant impact on sleep,
resulting in fatigue, poor work and school perfor-
mance, and missed days of work and school
[6,7,10,13]. We expect that those who report higher
scores on the CQ (more severe congestion) will also
report poorer sleep quality and greater daytime som-
nolence (MOS-SS); greater work, school and activity
impairment (WPAI-AS); and greater fatigue (PANAS-
Fatigue).
Discriminant validity. Total scores for the ﬁnal CQ
and the TSS were compared using anova with Scheffé
post-hoc pairwise comparisons for the three diagnostic
groups (conﬁrmed AR, Congestion, and control
patients). These analyses allowed evaluation of the
three groups for differences in self-reported severity
(TSS scores) and in the CQ.
Sensitivity and speciﬁcity. Following review of the
analyses listed above, performance of subsets of the
original 13 items of the CQ was evaluated using
the receiver operating characteristic (ROC) curve
analysis to see if the items discriminated between
groups [30,31]. The ROC is a graph plotting the true
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positive rate (sensitivity) versus the false positive rate
(1-speciﬁcity). An ROC curve helps make determina-
tions about a test’s ability to discriminate between
groups. In addition, ROC curves were used to deter-
mine the optimal cut point for scoring the ﬁnal subset
of items.
Results
A total of 354 patients were recruited from 49 sites:
284 patients (129 conﬁrmed AR patients and 155
Congestion patients) and 70 control subjects. Clinical
and demographic characteristics of the sample are pre-
sented in Table 2.
Item Selection
The 10 most common patient responses to the ARIQ
question about nasal stufﬁness/congestion are summa-
rized in Table 3. The most common general theme was
a complaint about breathing (e.g., difﬁculty breathing,
not able to breathe through nose, congested or stuffy).
The second most common theme related to rhinorrhea
symptoms (runny nose, having to blow nose, carrying
tissues). Draft CQ items were compared with the top
themes; matches were found for the top seven themes.
The 13 draft CQ items were subjected to a principal
components factor analysis (principal axis factoring)
and resulted in one primary factor (which explained
signiﬁcant variance in most of the items) and one sec-
ondary factor. The secondary factor accounted for
residual variance in two congestion items, suggesting
the central importance of congestion in the factor
structure of the CQ items. Varimax rotation (an
orthogonal rotation) yielded the most interpretable
factor structure. Items 12 and 13 (“Snoring” and
“Symptoms for more than 2 weeks”) did not load on
either of the two factors obtained, suggesting that their
content is sufﬁciently different from the remaining
items that they should not be included in an index of
screening items.
Table 2 Participant demographic and clinical characteristics at baseline (N = 354)
Characteristic
Control
(n = 70)
Congestion
(n = 155)
Allergic rhinitis
(n = 129)
Age (mean, SD) 46.6 (15.0) 45.5 (13.5) 41.5 (11.7)
Sex (n, %)
Male 30 (42.9) 45 (29.0) 36 (27.9)
Female 40 (57.1) 110 (71.0) 93 (72.1)
Race (n, %)
Caucasian 59 (84.3) 116 (74.8) 85 (65.9)
Black 5 (7.1) 23 (14.8) 8 (6.2)
Hispanic 2 (2.9) 14 (9.0) 20 (15.5)
Asian 3 (4.3) 0 (0.0) 15 (11.6)
Other 1 (1.4) 2 (1.3) 1 (0.8)
Domestic status (n, %)
Living alone 4 (5.7) 17 (11.0) 17 (13.4)
Living with a partner or spouse, family 66 (94.3) 137 (88.4) 110 (86.6)
Other 0 (0.0) 1 (0.6) 0 (0.0)
Employment status (n, %)
Employed full-time 36 (51.4) 101 (65.2) 80 (62.0)
Employed part-time 12 (17.1) 14 (9.0) 21 (16.3)
Homemaker 6 (8.6) 14 (9.0) 15 (11.6)
Student 3 (4.3) 5 (3.2) 4 (3.1)
Unemployed 3 (4.3) 6 (3.9) 4 (3.1)
Retired 8 (11.4) 12 (7.7) 2 (1.6)
Disabled 2 (2.9) 5 (3.2) 2 (1.6)
Other 0 (0.0) 3 (1.9) 3 (2.3)
Highest level of education (n, %)
Elementary/primary school 0 (0.0) 4 (2.6) 1 (0.8)
Secondary/high school 21 (30.0) 33 (21.3) 26 (20.2)
Some college 27 (38.6) 54 (34.8) 49 (38.0)
College degree 17 (24.3) 43 (27.7) 45 (34.9)
Postgraduate degree 5 (7.1) 17 (11.0) 8 (6.2)
Other 0 (0.0) 4 (2.6) 0 (0.0)
Table 3 Top ten qualitative themes derived from open-ended
Allergic Rhinitis Impact Questions
Theme
No. of
mentions
Content coverage
in CQ item(s)
Breathing 122 1, 4, 9, 10
Runny nose/blow nose/carry
tissues
105 6, 7
Headache 82 2
Sleep 70 11
Fatigue 70 11
Sinus/facial pressure 46 2
Work/study impact 42 8
Irritable/moody 41 NA
Watery/itching/burning eyes 34 NA
Sneezing 30 NA
CQ, Congestion Quantiﬁer; NA, not applicable.
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The squared multiple correlations, which indicate
items that do or do not measure common content,
support the conclusions of the factor analyses indicat-
ing that items 12 and 13 do not ﬁt with the remaining
set of items (Table 4). In addition, items 3, 5, 7, and 10
have weaker relationships to the other items. Follow-
ing deletion of items 12 and 13, squared multiple
correlations of the reduced set of 11 items were com-
puted and supported removal of items 3, 5, 7, and 10.
Comparison to ARIQ patient themes indicates
adequate content coverage with the remaining seven
items. These seven items (items 1, 2, 4, 6, 8, 9, and
11—italicized in Table 1) were evaluated further for
screener performance.
Reliability
Internal consistency reliability of the seven items was
acceptable (alpha = 0.93). The average interitem cor-
relations and “alpha-if-deleted” are nearly identical
for all items. To evaluate test–retest reliability, the ICC
for the CQ scores for stable patients was calculated.
Patients were considered “stable” if they noted that
their overall allergy (n = 161) and congestion symp-
toms (n = 172) had not changed or changed minimally
during the 15 days of the study. The ICC for the visit 1
(baseline) and visit 3 (Day 15) CQ was 0.85, indicating
good test–retest reliability.
Screener Discrimination
The ROC curves were calculated to compare the con-
ﬁrmed AR patients and the Congestion patients with
the controls. As the area under the curve (AUC)
increases toward 1.0, the better the test discriminates
cases from controls. As an additional comparison to
explore the sensitivity and speciﬁcity of the seven-item
CQ to discriminate, we compared the conﬁrmed AR
with the Congestion patients. When comparing con-
ﬁrmed AR patients with controls, the AUC was 0.97.
For the comparison of the Congestion patients and
controls, the AUC was 0.94. In both instances, the
seven items allow for extremely good discrimination
between two types of patients and controls. The two
symptomatic patient groups were indistinguishable
(AUC = 0.45).
Assessing the CQ’s ability to discriminate between
patients with no congestion and those being evaluated
for AR symptoms represents an extreme comparison.
Moreover, the control patients were more likely to be
male than were the two patient groups. To help guard
against a potential confound due to sex and to make a
more compelling case for the CQ’s ability to discrimi-
nate, a series of tests were conducted to compare
patients with different levels of severity of AR symp-
toms. We calculated mean baseline TSS scores, which
indicate severity of AR symptoms (range = 0–27), for
each of the three patient groups. T-tests were used to
compare the mean TSS scores by patient group. Not
surprisingly, the Controls have signiﬁcantly less
(P < 0.001) severe AR symptoms for both the AM and
prior 12-hour scores ( X¯= 1.90, SD 3.61; X¯= 2.11, SD
3.45, respectively) compared with the AR ( X¯= 13.49,
SD 6.11; X¯= 14.67, SD 5.82) and Congestion patients
( X¯= 12.61, SD 6.96; X¯= 14.11, SD 5.77). The mean
TSS scores for the Congestion and AR patients are not
signiﬁcantly different from each other.
We then created quartiles of symptom severity (TSS)
to evaluate the ability of the CQ to discriminate
between these severity levels. Based on the ﬁndings of
the previous ROC curves and the t-tests comparing the
TSS scores, the conﬁrmed AR and Congestion patients
were combined for the analyses comparing quartiles of
symptom severity. When comparing the most severe
with the least severe patients on the AM TSS, the AUC
is 0.81; the seven-item screener can discriminate
between these two groups. Comparing the highest
quartile with the slightly more severe quartile, the
AUC is 0.75. Finally, the AUC for the comparison of
the highest symptom severity quartile with the second
highest is 0.63. The results for analyses based on the
quartiles of the prior 12-hour symptom severity score
were similar, though somewhat attenuated (AUC
ranged from 0.68 to 0.58), suggesting slightly reduced
salience of the prior 12-hour symptoms compared with
morning symptoms.
Empirical Validation
The seven-item nasal CQ was correlated with several
key criterion variables. The 11-item version was
included as a comparison to evaluate the extent to
which the item reduction decreased the predictive
ability of the shorter version. Table 5 presents the cor-
relations of the 11- and seven-item screener versions
with the WPAI, PANAS, and MOS Sleep Scale sub-
scales for conﬁrmed AR and Congestion patients com-
bined. Correlations with the WPAI ranged from 0.28
to 0.61, indicating that increased congestion is
Table 4 Squared multiple correlations of congestion screener
items
Screener item
Squared multiple
correlation—
13 items
Squared multiple
correlation—
11 items
1. Stufﬁness 0.78 0.77
2. Sinus pain 0.64 0.64
3. Ear popping 0.56 0.55
4. Mouth breathe 0.69 0.67
5. Smell 0.58 0.56
6. Clearing nose 0.68 0.68
7. Runny nose 0.51 0.49
8. Work/school impact 0.65 0.63
9. Morning stufﬁness 0.77 0.77
10. Morning thirst 0.54 0.51
11. Sleep impact 0.76 0.75
12. Snoring 0.11
13. Symptoms for more than
2 weeks?
0.16
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signiﬁcantly related to work time missed, work and
class impairment, and activity impairment. Very few
patients were taking classes; therefore, correlations
between the CQ and class time missed and overall class
impairment, while moderate and in the same direction
as the other correlations, were not statistically signiﬁ-
cant. The CQ score was signiﬁcantly associated with
the PANAS subscales: those with a higher CQ score
reported greater sadness, less joviality, and greater
fatigue. Finally, the CQ was moderately and sig-
niﬁcantly correlated with sleep disturbance, sleep
adequacy, daytime somnolence, shortness of breath,
and the two sleep problem indices. Neither the 11-item
nor the seven-item versions were correlated with the
snoring subscale. Moreover, the seven-item version
was not signiﬁcantly correlated with sleep quantity,
although the coefﬁcient was only slightly smaller than
that of the 11-item version. In almost all instances, the
correlations for the seven-item version with the criteria
are the same or very similar to those of the 11-item
version.
Finally, patients were asked about the direction and
extent of change they have experienced in nasal con-
gestion, morning symptoms, and overall allergy symp-
toms. As expected, an improvement in CQ scores was
positively correlated with the global change variables.
That is, improvement in the CQ score from baseline to
Day 15 was strongly correlated with the patients’
assessment of improvement in nasal congestion (r =
0.77), morning symptoms (r = 0.77), and overall
allergy symptoms (r = 0.74).
Congestion Quantiﬁer Sensitivity
An important dimension of instrument development is
determining a meaningful summative score that can
help establish which patients are in greatest need for
intervention (i.e., a cut point). ROC analyses were
used to determine a cut point by balancing the propor-
tion of respondents who are correctly identiﬁed as
congested (true positive) with those that are not con-
gested but are identiﬁed as such (false positive). The
ﬁnal cut point is one that strikes a balance between
sensitivity and speciﬁcity, and correctly identiﬁes the
greatest proportion of patients with substantial con-
gestion without incorrectly identifying patients as
having substantial congestion when in fact they do not.
The ROC analysis indicates that a total, summed score
on the CQ7 of 7 (out of a range of 0–28) yields a
balance of sensitivity (91%) and speciﬁcity (86%), and
that 90% of cases are correctly classiﬁed. In other
words, for purposes of screening, a total score of 7
would indicate that a patient’s responses to these seven
items are severe enough to consider seeking treatment.
Discussion
This study presents development of a screening instru-
ment for nasal congestion and demonstrates that a
seven-item version—the Congestion Quantiﬁer 7 or
CQ7—can distinguish cases from controls at accept-
able levels. The CQ7 can also distinguish patients with
different levels of severity of AR symptoms. Moreover,
the CQ7 appears to be sensitive to changes in patient
condition. Changes in the congestion screener across
15 days were signiﬁcantly and substantially correlated
with a patient-reported assessment of change in overall
allergy symptoms, morning allergy symptoms, and
nasal stufﬁness and congestion.
The CQ7 is designed as a screener for patients with
congestion to help them recognize the need to seek
medical advice. Patients may already know that they
have nasal congestion; they may not realize, however,
that any comorbid medical complaints, sleep distur-
bance, or work and school impact are possible conse-
quences of their congestion. By quantifying the impact
of these congestion-related consequences, the patient is
alerted (by a numeric value) to seek medical advice.
The original set of 13 items, derived from research
literature and clinician input, was reduced to seven
items based on patient input to open-ended questions,
which provided conceptual and content guidance, and
empiric item performance. The CQ7 demonstrates
high internal consistency reliability, good test–retest
reliability, and construct validity based on relation-
ships with other PROs. It should be noted that while
the alpha reliability was very good (0.93) suggesting
high internal consistency, individual items of the CQ
showed variability in their relationships with the cri-
terion variables (not presented here). This suggests that
Table 5 Construct validation of congestion
screener—correlation to WPAI, PANAS, and MOS Sleep Scales
(conﬁrmed AR and Congestion patients only, combined)
AR and congestion 11 items 7 items
WPAI
Work time missed 0.28* 0.29*
Work impairment 0.61† 0.59†
Overall work impairment 0.58† 0.57†
Class time missed (n = 16) 0.40 0.29
Impairment in class 0.55† 0.54†
Overall class impairment (n = 16) 0.59 0.44
Activity impairment 0.67† 0.66†
PANAS
Sadness 0.32† 0.27†
Joviality -0.39† -0.40†
Fatigue 0.54† 0.53†
MOS-12
SPI I 0.65† 0.65†
SPI II 0.67† 0.66†
Sleep disturbance 0.57† 0.57†
Sleep adequacy -0.37† -0.36†
Somnolence 0.53† 0.51†
Snoring 0.21 0.21
Shortness of breath/headache 0.50† 0.51†
Sleep quantity -0.23‡ -0.21
*P < 0.01; †P < 0.001;
‡
P < 0.05.
AR, allergic rhinitis; MOS, Medical Outcomes Study; PANAS, Positive Affect
and Negative Affect Scale; WPAI, Work Productivity and Activity Impairment
Questionnaire.
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using more than one variable to assess congestion and
its impact increases the chances of capturing these
patient-reported salient symptoms and their effects,
yielding a more comprehensive and sensitive tool.
Patients with higher CQ7 scores consistently
reported negative impacts more than those with lower
CQ7 scores. Higher CQ7 scores were related to more
missed work; more work, class, and activity impair-
ment; greater fatigue; greater sleep disturbance, lesser
sleep adequacy, and increased daytime somnolence.
They also noted more shortness of breath and head-
aches. Patients with higher CQ7 scores also experi-
enced more negative emotional consequences, such as
greater sadness and less joviality. The correlation of the
CQ7 with the WPAI-AS (work and school impact) was
expected, since both measures include questions asking
about impact on work and school. Nevertheless,
patients noted that these are signiﬁcant effects of con-
gestion. These results suggest that the CQ7 adequately
captures this content without having to ask a separate
set of questions such as the WPAI-AS.
The ﬁndings of this study suggest that this brief
screening instrument is able to capture symptoms and
their impacts that are salient to patients, can discrimi-
nate between different levels of severity, and can detect
changes that are concordant with changes in other
dimensions relevant to patients. The initial, 11-item
version of the CQ was relatively brief, but analyses
indicate that item reduction does not diminish sensi-
tivity and speciﬁcity. The seven-item version also mea-
sures work and sleep impact, two areas prominent in
patient reports of congestion impact on the open-
ended items.
A screening tool for nasal congestion has relevance
to patients, clinical care, and public health. First, con-
gestion is not a trivial condition; it has a very large
impact on patients, the workplace, and the health-care
system. Second, in most instances, it is a treatable
condition. Third, evidence indicates that the majority
of patients with congestion go undiagnosed. Fourth,
for patients, congestion is one of the, if not the, most
salient and troublesome symptoms of AR. Related to
this, there is evidence that many patients experience
low levels of congestion that impede breathing and
daily function but do not seek treatment, perhaps
because they do not realize that treatment is available
or because they become somewhat desensitized to it.
Hence, methods that encourage patients to seek treat-
ment will be broadly beneﬁcial. The value of the CQ7
is that it raises awareness of congestion in both the
patient and the clinician by encouraging them to focus
on it and, furthermore, quantify it. This provides an
opportunity to trigger appropriate care which can lead
to improved health.
There are two main reasons for using multiple ques-
tions to evaluate nasal congestion and its impact. From
the patients’ standpoint, the impact of congestion is
multiple, as noted in their responses to the open-ended
questions that asked about the greatest impact of
morning allergy symptoms and nasal stufﬁness/
congestion on their lives. From a statistical standpoint,
it is preferable to use more than one question to ask
about congestion and its impact. Although the alpha
reliability for the CQ7 was quite high, the differential
relationships of items with criteria suggests that better
coverage of these concerns is attained when these seven
items are used rather than a single question asking
about severity of congestion.
To date, no short, patient-completed instrument
based on patient and clinician input exists for nasal
and sinus symptoms associated with congestion. The
CQ developed in this study can ﬁll the need for a quick
method of clinician or patient self-identiﬁcation of key,
clinically valid, and patient-relevant symptoms of con-
gestion that warrant evaluation. A summed score of 7
was found to be useful for correctly classifying patients
(i.e., a cut point that minimizes false positives).
Patients or clinicians can easily add up the scores for
responses to the seven items. If a score of 7 or greater
is attained, the patient can be encouraged to discuss
with their doctor possible treatment options. Future
research will explore both the clinical signiﬁcance of
this scoring and the utility of the CQ7 for monitoring
patients’ progress under treatment.
The CQ7 is not intended to replace careful clinical
diagnosis; rather it can aid clinicians and patients by
allowing patients to identify clinically meaningful,
chronic congestion symptoms and encourage them to
seek appropriate medical treatment or patient self-
care. Moreover, it can provide a focal point for
patients and clinicians by highlighting symptoms that
may need more thorough examination. Similar screen-
ing and monitoring strategies have been developed for
other disorders such as asthma, including the Asthma
Control Test [32] and the Asthma Control Ques-
tionnaire [33]. Measures suitable for patient self-
completion can improve clinical management through
appropriate case ﬁnding.
Source of ﬁnancial support: This study was funded by a
research grant from Schering-Plough.
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